🔔 After the Bell
🎯 Session Review
Markets kicked off April with solid gains Wednesday, as tech stocks led a broad rally that pushed the Nasdaq up 1.16% to close at 21,840.95. The S&P 500 climbed 0.72% to 6,575.32, while the Dow Jones added 0.48% to finish at 46,565.74. Trading volume picked up as investors digested a major SpaceX IPO filing and fresh regulatory wins in the pharma sector.The session's headline grabber came from Elon Musk's private space venture, with SpaceX officially filing to go public in what could become one of the largest IPOs in history. The company plans to raise between $40 billion and $80 billion, giving investors their first chance to own a piece of the satellite launch and AI infrastructure business. SpaceX also announced plans for an analyst day on April 21st, followed by tours of its Macrohard xAI datacenter in Memphis two days later.
Healthcare stocks caught a bid after the FDA approved Eli Lilly's (LLY) new GLP-1 pill called Foundayo, sending shares up $34.51 to $954.28. The once-daily pill offers a more convenient alternative to Lilly's weekly Zepbound injection, potentially expanding the addressable market for weight loss treatments despite being slightly less effective than the injectable version.
📊 Today's Market Movers
|
▲ Gainers
|
▼ Losers
|
🚀 Key Catalysts
The tech sector powered Wednesday's advance, with semiconductors posting particularly strong gains. Micron (MU) surged enough to add $43.8 billion to its market value in a single session, marking its biggest annual gain and nearing a record market cap increase. The memory chip maker's rally reflects growing optimism around AI infrastructure demand and data center buildouts.Speaking of data centers, Oracle (ORCL) got a boost from Bloomberg News reporting that Related Digital is close to securing $16 billion in financing for a massive Oracle data center. The deal, which took several months of investor negotiations to hammer out, underscores the frenetic pace of investment flowing into AI and cloud computing infrastructure.
Not everything sparkled on Wednesday. Apple (AAPL) faced negative headlines as its fitness chief retired amid harassment allegations, a notable departure for an executive who played a crucial role in the company's expansion into fitness technology and services. Retail also struggled, with Nike (NKE) plunging $8.19 to $44.62 and luxury furniture retailer RH crashing $26.98 to $112.84, suggesting consumer spending pressures remain a concern.
Sponsored Content
STOCK WARNING: Move Your Money This Monday
STOCK WARNING: Move Your Money This Monday 20-year trading veteran Tim Bohen just identified a dirt-cheap stock that could soar 100% or MORE this coming Monday – click here for the full details on this urgent opportunity now . You are receiving this email because you opted in to receive financial news and updates.
🎭 Investor Mood
Investor Pulse: SpaceX Euphoria
Investor sentiment turned decidedly bullish Wednesday, fueled by the prospect of accessing SpaceX equity for the first time and continued momentum in the AI infrastructure buildout. The SpaceX IPO filing represents a watershed moment, potentially unlocking tens of billions in value for retail and institutional investors who have watched from the sidelines as private valuations soared.The healthcare sector's gains on Eli Lilly's FDA approval added to the positive vibe, though CEO Dave Ricks threw cold water on the Trump administration's drug pricing proposals. In a CNBC interview, Ricks rejected the White House's efforts to formalize Most Favored Nations pricing, joining over a dozen pharmaceutical companies opposing the policy. Despite this political headwind, investors focused on the commercial opportunity presented by Foundayo's approval.
Underneath the surface optimism, some cracks appeared. Pfizer (PFE) and BioNTech (BNTX) paused U.S. recruitment for a COVID vaccine study targeting healthy adults aged 50 to 64 due to insufficient participant interest, a sign that pandemic fatigue continues to weigh on public health initiatives. Treasury yields ticked slightly higher across the curve, with the 10-year rising to 4.32%, while the dollar index slipped to 99.63 as risk appetite returned.
🔍 5 Focus Points for Tomorrow
| 📊 | SpaceX analyst day scheduled for April 21st |
| 🤖 | Continued momentum in AI infrastructure investments |
| 📊 | GLP-1 weight loss drug competition heating up |
| 🏛️ | Treasury yields holding near 4.30% on 10-year |
| 📊 | Consumer discretionary weakness in retail names |
Sponsored Content
Iran Conflict Reveals Trump's Most Powerful Weapon
It's not missiles. It's not sanctions. It’s not tariffs. It’s a commodity found in the Appalachian Mountains. America controls 80% of the one material every enemy nation needs to build advanced technology — semiconductors, AI chips, military electronics. Trump is expected to weaponize this monopoly with an export ban that cuts off China and Iran overnight. Morgan Stanley estimates the reshoring boom triggers a $10 trillion transformation. See the full story here .
💸 Bottom Line
Wednesday's session reinforced the market's fascination with AI infrastructure and transformative healthcare treatments, themes that have dominated 2026 trading. The SpaceX IPO filing could set the stage for a blockbuster offering that reshapes how investors access space economy and AI opportunities, assuming market conditions remain favorable through the expected listing date.Elsewhere, Franklin Templeton (BEN) announced plans to acquire digital assets firm 250 Digital, which will fold into a new Franklin Crypto division as the traditional asset manager expands its cryptocurrency capabilities. Meanwhile, Meta (META) caught a break as a judge threw out a whistleblower case from WhatsApp's former security chief, ruling insufficient evidence existed to prove he was wrongfully dismissed for raising user safety concerns.
Looking ahead, investors should monitor how the SpaceX analyst day on April 21st shapes IPO demand and whether the company provides concrete guidance on its AI datacenter business. On the healthcare front, watch for competitive responses to Lilly's pill approval and any legislative movement on drug pricing proposals. With tech leading the charge and consumer stocks struggling, the divergence between growth and value continues to widen as we move deeper into Q2.
A tale of two cities [ad]